{"id":"NCT02013531","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms","officialTitle":"Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-05","completion":"2014-06","firstPosted":"2013-12-17","resultsPosted":"2016-03-29","lastUpdate":"2016-03-29"},"enrollment":37,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder","Anxiety"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response.","primaryOutcome":{"measure":"Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline, Week 6","effectByArm":[{"arm":"Brexpiprazole","deltaMin":-19.6,"sd":1.5}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":21},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":["34894307","27781135"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":37},"commonTop":["Increased appetite","Diarrhoea","Dry mouth","Dizziness","Musculoskeletal stiffness"]}}